With group net sales of JPY SRL offers comprehensive clinical laboratory testing services to medical institutes throughout the nation, ranging from general testing to esoteric testing, including gene-based tests. Caris Life Sciences, a leading biosciences company, specializes in the development and commercialization of the highest quality anatomic pathology, molecular profiling and blood-based diagnostic technologies, in the fields of oncology, dermatopathology, hematopathology, gastrointestinal pathology and urologic pathology.
The company provides academic-caliber consultations for thousands of patients a day, through its industry-leading team of expert, subspecialty pathologists. Caris also offers advanced molecular analyses of patient samples through prognostic testing services and genomic, transcriptomic, and proteomic profiling to assist physicians in their treatment of cancer.
The company is headquartered in the Dallas metroplex, and operates laboratories at the headquarters, as well as in the Phoenix and Boston metro areas.
Carie infection gorge
Miraca Holdings Inc. Caris Life Sciences Holly R. The Caris Life Sciences partnership with Ambry Genetics will allow physicians to order Caris' tumor profiling and Ambry's germline genetic testing from one service provider and receive a comprehensive report with somatic and germline results to inform medical management.
At Caris, we explore ways to improve patient care, enhance the healthcare delivery system, and transform precision medicine into reality. We are pleased to welcome the University of Minnesota Masonic Cancer Center to the CarisPOAa collaborative network dedicated to advancing the role of precision medicine in cancer treatment.
CarisLS is revolutionizing precision medicine to provide physicians and patients with the highest quality information about their health. Please join us today for a poster session at SNO19 to learn about differences in adolescent, young and older adult gliomas based on functional molecular subgroups. Please join us today for a poster session at SNO19to learn more about treatment strategies for a class of tumors with historically dismal prognosis.
We are at SNO19 today! Visit our booth to see the advances CarisLS is making to improve patient outcomes. Caris Molecular Intelligence helps oncologists navigate therapies with benefit and avoid drugs with a lack of benefit. Armonk, N. This poses information overload challenges for oncologists who need to make treatment decisions in real time. To help meet this need, Caris is using multiple technologies to develop world-class molecular profiling services that help doctors advance evidence-based, personalized treatment options for cancer patients.
It has tested more than 65, cancer patients for 70 different molecular markers using multiple technology platforms. These markers are then correlated with 55 FDA-approved cancer therapies and hundreds of clinical trials agents. The Caris tumor profiling database is one of the largest datasets in the application of advanced molecular profiling technologies to support clinicians in delivering personalized treatment recommendations — or precision oncology.
It also has to be stored for years and be organized in a manner that facilitates deep analytic evaluation and ensures data security. This enhanced infrastructure leverages the broadest range of IBM technologies in the life sciences industry.